Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-16
DOI
10.1007/s00262-020-02646-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma
- (2018) Jacques Raphael et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
- (2018) Jason Shafrin et al. HEALTH POLICY
- Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
- (2018) Martin Reck Immunotherapy
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost–effectiveness analysis
- (2018) Ahmad Tarhini et al. Immunotherapy
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL
- (2017) Alberto Russi et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma
- (2017) Christine G. Kohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
- (2017) Mahdi Zargar et al. ONCOLOGIST
- Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆
- (2017) Matthew C. Ward et al. ORAL ONCOLOGY
- Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
- (2017) Min Huang et al. PHARMACOECONOMICS
- Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
- (2017) Luis Silva Miguel et al. VALUE IN HEALTH
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
- (2017) Jingshu Wang et al. Journal of Managed Care & Specialty Pharmacy
- Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting
- (2016) Beatriz Guglieri-López et al. ANTI-CANCER DRUGS
- A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
- (2016) Klazien Matter-Walstra et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
- (2016) Megan A. Bohensky et al. VALUE IN HEALTH
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
- (2016) Ron Goeree et al. JOURNAL OF MEDICAL ECONOMICS
- Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting
- (2015) Edmond L. Toy et al. CURRENT MEDICAL RESEARCH AND OPINION
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Comparative healthcare costs in patients with metastatic melanoma in the USA
- (2015) Chun-Lan Chang et al. MELANOMA RESEARCH
- The cost of ipilimumab toxicity
- (2015) Nadia Yousaf et al. MELANOMA RESEARCH
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
- (2014) Patti Curl et al. PLoS One
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings
- (2013) Anthony Jarkowski et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Health outcomes in economic evaluation: the QALY and utilities
- (2010) S. J. Whitehead et al. BRITISH MEDICAL BULLETIN
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now